IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist
19.6.2026 09:00:00 CEST | Business Wire | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications.
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/

From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer.
Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level consistency across IQM's technology.
“Ciesla's track record of scaling complex instrumentation platforms and building world-class R&D organizations makes him an exceptional addition to our leadership team,” said Jan Goetz, CEO and Co-founder of IQM Quantum Computers. “As we accelerate our path toward fault-tolerant quantum computing, his experience integrating hardware and software systems at scale will be invaluable. I also want to thank Inés for her outstanding contributions over the years, and I am pleased she will continue to shape our technology roadmap in her new role.”
Ciesla is an accomplished innovator and product development leader with a proven track record and is an inventor of more than 100 patents and patent applications. He most recently served as Vice President of Engineering at 10x Genomics (Nasdaq: TXG) and previously held leadership roles at companies including Illumina (Nasdaq: ILMN) Lumentum (formerly Nasdaq: JDSU), Intel (Nasdaq: INTC), and Tactus Technology.
He also has significant board experience, serving on the Board of Directors of Lightwave Logic, Inc., (Nasdaq: LWLG) complemented by an academic background that includes a PhD in Physics from Heriot-Watt University.
"IQM has established itself as an industry leader in quantum computing through a combination of technological excellence, real-world deployments, and disciplined execution. What attracted me to the company is its commitment to building production-grade quantum systems that customers can own, operate, and build value on — not just promises of what quantum could one day do," said Craig Ciesla.
These appointments come as IQM continues to scale its technology roadmap and operations as a fully vertically integrated quantum computing company — operating its own chip factory and assembly line, and having sold 23 quantum computers to date, more than any other manufacturer.
"Over the past years, I have seen first-hand how IQM has evolved from an ambitious deep-tech venture into a company delivering quantum computers to some of the world's leading research institutions and supercomputing centers," said De Vega. "I look forward to further contributing to the company's growth trajectory."
Throughout her career, she has led a team responsible for developing and implementing quantum algorithms across a wide range of quantum computing applications, while developing advanced tools to tackle errors in quantum computers.
Furthermore, she has been a researcher in several academic institutions, such as the Max Planck of Quantum Optics, the University of Ulm, and the Ludwig Maximilian University of Munich, where she is currently associated to the department of Theoretical Nanophysics.
IQM is nearing its Nasdaq listing through a planned merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). The transaction has gained momentum since February, with an upsized PIPE of $146 million in early June after Finnish pension insurer Ilmarinen joined existing institutional investors.
About IQM Quantum Computers
IQM Quantum Computers is a global leader in superconducting quantum computers, delivering full-stack quantum computers and cloud platform access to research institutions, universities, high-performance computing centers, national laboratories and enterprises worldwide. IQM's on-premises deployment model gives customers direct ownership and control of their quantum infrastructure. Founded in 2018, headquartered in Finland with major operations in Munich, it has over 400 employees. IQM operates across Europe, Asia, and North America. IQM filed an F-4 registration statement with the SEC, which has since been declared effective, with the intention to become the first publicly listed European quantum company on Nasdaq Global Exchange in the U.S by merging with Real Asset Acquisition Corp. (Nasdaq: RAAQ).
View source version on businesswire.com: https://www.businesswire.com/news/home/20260619693929/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
TestMu AI Launches Official n8n partner integration, Bringing Real Browser Infrastructure to AI Agent Workflows18.6.2026 15:25:00 CEST | Press release
Developers can now access TestMu AI Browser Cloud directly from n8n workflows, enabling AI agents to operate across 3,000+ browser and operating system environments TestMu AI (formerly LambdaTest), the world's first Full-Stack Agentic AI Quality Engineering platform, today announced the launch of its official TestMu AI Agent partner integration for n8n, one of the fastest-growing workflow automation platforms for AI agents and enterprise automation. Available as an n8n verified and partnered Community Node, the TestMu AI Agent integration enables developers to connect AI agents and automated workflows to TestMu AI's Browser Cloud, providing access to more than 3,000 browser, operating system, and device environments without requiring single line of code as well. As organizations increasingly adopt AI agents for business automation, browser access has emerged as a critical capability. The new integration allows n8n users to equip their workflows with real cloud-hosted browsers capable o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom